Renalytix (Reg S) (RENX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 6.25p
   
  • Change Today:
      0.000p
  • 52 Week High: 12.50
  • 52 Week Low: 5.62
  • Currency: UK Pounds
  • Shares Issued: 437.02m
  • Volume: 98,386
  • Market Cap: £27.31m
  • RiskGrade: 348

Latest ShareCast News

Renalytix reports progress in expanding US testing

By Josh White

Date: Tuesday 09 Dec 2025

(Sharecast News) - Renalytix said in an update on Tuesday that it was making progress in expanding the use of KidneyIntelX.dkd across the United States, reporting growing testing volumes, new state coverage and advancing commercial partnerships ahead of its annual general meeting in London.

Renalytix shares more than double after striking US diagnostics partnership

By Iain Gilbert

Date: Monday 15 Sep 2025

(Sharecast News) - Medical diagnostics firm Renalytix said on Monday that it has struck a definitive agreement with Tempus AI to accelerate the adoption of its kidneyintelX.dkd test to support early-stage risk assessment in chronic kidney disease, slow progression, and improve patient outcomes.

Renalytix enters new collaboration with NYKHM

By Josh White

Date: Tuesday 03 Jun 2025

(Sharecast News) - Renalytix announced a new collaboration with New York Kidney & Hypertension Medicine (NYKHM) on Tuesday, aimed at expanding access to its FDA-approved kidneyintelX.dkd test across underserved communities in the Greater New York area.

Renalytix Q3 revenues up 20pc 10-Apr-2025 ShareCast
Renalytix terminates formal sale process 20-Aug-2024 ShareCast
Renalytix test gets US Medicare coverage determi... 14-Jun-2024 ShareCast
Renalytix surges on takeover approach 04-Mar-2024 ShareCast
Renalytix shares jump on draft US Medicare cover... 09-Feb-2024 ShareCast
Renalytix kidney test claims allowed by US Paten... 06-Oct-2023 ShareCast
Renalytix gets KidneyIntelX included in major cl... 21-Aug-2023 ShareCast
Renalytix launches kidney disease test in Arabia... 21-Jul-2023 ShareCast
Renalytix test gets US FDA marketing authorisation 30-Jun-2023 ShareCast
Renalytix secures expanded coverage in Washingto... 22-May-2023 ShareCast
Renalytix reports positive study on clinical val... 19-Apr-2023 ShareCast
Renalytix rises on publication of positive evide... 29-Nov-2022 ShareCast
Renalytix reports positive outcomes from Mount S... 10-Jun-2022 ShareCast
Renalytix completes financing to support its gro... 08-Apr-2022 ShareCast
Revenue rises, losses widen in first half at Ren... 31-Mar-2022 ShareCast
Renalytix hits patient milestone for kidney and ... 29-Mar-2022 ShareCast
Renalytix launches new US provider access portal 09-Mar-2022 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

RENX Market Data

Currency UK Pounds
Share Price 6.25p
Change Today 0.000p
% Change 0.00 %
52 Week High 12.50
52 Week Low 5.62
Volume 98,386
Shares Issued 437.02m
Market Cap £27.31m
RiskGrade 348

RENX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend Not Available
Income Not Available
Growth Not Available

RENX Dividends

No dividends found

Trades for 11-Dec-2025

Time Volume / Share Price
15:31 80 @ 6.20p
12:58 6 @ 6.50p
11:57 2,256 @ 6.20p
11:24 18,253 @ 6.30p
11:21 50,000 @ 6.21p

RENX Key Personnel

CEO James Renwick McCullough

Top of Page